Phyton Biotech Continues to Expand its Team of Scientists
Dr. Marisol Ochoa-Villareal joins the Company’s R&D Team in Germany.
Delta, Canada, May 4, 2022 — Phyton Biotech, Ltd., a global leader in specialty fermentation solutions for naturally derived compounds and the largest global supplier of Paclitaxel and Docetaxel via Plant Cell Fermentation® (PCF), is delighted to announce that Dr. Marisol Ochoa-Villarreal has joined its team as a Scientist in the Company’s Research and Development Department.
Ochoa-Villareal is a recognized expert in paclitaxel biosynthesis, with a specific focus on the metabolic engineering of secondary metabolites and plant tissue culture. She joins Phyton’s team at the Company’s cGMP certified facility in Ahrensburg, Germany. Her work will further contribute to Phyton’s ongoing leadership as the world’s foremost provider of “green” PCF® Technology.
“Phyton Biotech is delighted to announce that Marisol Ochoa-Villarreal is joining our team of Scientists in the R&D department,” said Colin Marr, President of Phyton Biotech. “Marisol has a strong background in the metabolic engineering of secondary metabolites and plant tissue culture, and her decision to join us demonstrates Phyton’s ongoing ability to attract the very best talent. Please join us in welcoming Marisol Ochoa-Villarreal to the team.”
Originally from Mexico, Ochoa-Villareal holds a PhD in Plant Molecular Biology from the University of Edinburgh (UK), an MS in Plant Sciences from the Research Centre in Food and Development (Mexico), and a BE in Biochemical Engineering from the Institutio de Tepic (Mexico).
ABOUT PHYTON BIOTECH
Phyton Biotech, a wholly-owned subsidiary of DFB Pharmaceuticals, is a global leader in Plant Cell Fermentation (PCF®) Technology, offering comprehensive services for the development and commercialization of plant-based molecules, extracts and recombinant products, serving the pharmaceutical, Chinese Traditional Medicine, cosmetic, agricultural and food ingredient industries. Using PCF®, Phyton Biotech offers a time, risk and cost-balanced path to commercially viable production processes, overcoming limitations often experienced with traditional plant extraction and chemical synthesis. As a biotechnology leader with certified GMP facilities in Germany and Canada, Phyton Biotech has a successful track record of developing and implementing innovative specialty fermentation solutions for naturally derived compounds for clients around the world. The company is now the world’s largest producer of paclitaxel and docetaxel via PCF®, with the capacity to meet more than one-third of the global demand for these critical active pharmaceutical ingredients.